Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
-
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
BLISS-LN achieves primary endpoint and all major secondary endpoints. On-track for regulatory submission during the first half of 2020.
-
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
GSK announced treatment with the investigational single-agent belantamab mafodotin
-
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
ViiV files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
-
GSK employees celebrate #GivingTuesday with $190,000 in awards to local nonprofits
GSK announced on #GivingTuesday that its employees have selected 19 local nonprofit organizations to each receive $10,000 charitable gifts
-
GSK awarding $400,000 to Greater Philadelphia nonprofits making an IMPACT on health outcomes
GSK today honored 10 local nonprofits that help foster a healthier Philadelphia region.
-
GSK awards Triangle nonprofits making a powerful IMPACT on health outcomes
Ten North Carolina nonprofits will each receive a $40,000 GSK IMPACT Award
-
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
-
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic.
-
GSK receives prestigious Prix Galien USA award for SHINGRIX
SHINGRIX recognized as 2019 Best Pharmaceutical Product, following Galien Award win in Germany last week.
-
GSK announces new events in the "Us in Lupus" campaign to reach women of color
The initiative complements the virtual Us in Lupus program, an online education program and community for people diagnosed with lupus.
-
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib)...
-
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
-
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
-
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
-
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV
Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.
-
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Phase 3 PRIMA trial of Zejula® (niraparib)
-
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)
Data presented at ESMO 2019 support phase II/III registrational trial with pembrolizumab in first-line recurrent/metastatic HNSCC.
-
GSK invests $120 million in next-generation US biopharmaceutical manufacturing facility
GSK today announced a $120 million investment to expand its manufacturing facility in Upper Merion, Pennsylvania.
-
Real-world effectiveness evidence among GSK data presented at ERS 2019
Real-world effectiveness evidence among GSK data presented at ERS 2019
